



## Nanoroadmap Conferences

Present Forecast at 2015 of Nanotechnology Application in:  
Materials, Health and Medical Systems, Energy

*Project co-founded by the EC in the Sixth Framework Programme (FP6 - Thematic Priority 3)*

# Present Forecasts at 2015 of Nanotechnology Application in: Materials, Health and Medical Systems, Energy

Padova, November 10, 2005

## NANOTECHNOLOGY AND THE NANOROADMAP PROJECT

**Elvio Mantovani**

AIRI/Nanotec IT-Rome (Italy)


[www.nanotec.it](http://www.nanotec.it) - [info@nanotec.it](mailto:info@nanotec.it)

*E. Mantovani*

---



# ESTIMATE of PUBLIC FUNDING for R&D in NANOSCIENCE and NANOTECHNOLOGY WORLDWIDE (1997 – 2005) (US\$ million)




Origin: Roco NSF 2005

Others include: Australia, China, Eastern Europe, FSU, South Korea, Singapore, Taiwan and other countries with nanotechnology R&D.

E. Mantovani

# Private and Public Expenditures in 2004



*Origin: Lux Research & NSF (public includes national, regional and state funding)*

# Nanotechnology Application


The sectors which will gain most from nanotechnology are:

- MATERIALS & MANUFACTURING
- MEDICAL AND PHARMACEUTICAL APPLICATIONS
- ELECTRONICS

AROUND 70% OF THE NANO-RELATED MARKET WILL BE SIZED BY THESE SECTORS.

# R&D Challenges

- **UNDERSTANDING AND CONTROLLING NANOSCALE PHENOMENA AND PROCESSES**
- **NANOSTRUCTURES HANDLING & MASS PRODUCTION**
- **INTEGRATE TOP-DOWN AND BOTTOM-UP APPROACHES**
- **INTERFACE OF LARGE SYSTEMS WITH NANOSYSTEMS**



# The Nanoroadmap Project



[www.nanoroadmap.it](http://www.nanoroadmap.it)

[info@nanoroadmap.it](mailto:info@nanoroadmap.it)

## OBJECTIVE

- PREPARATION OF ROAD MAPS (AT 10 YEARS) FOR THE APPLICATION OF NANOTECHNOLOGY IN THREE SECTORS:
  - MATERIALS
  - HEALTH AND MEDICAL SYSTEMS
  - ENERGY

## DURATION

- JANUARY 2004-DECEMBER 2005

*E. Mantovani*

---



# The Partners



AIRI/Nanotec IT / (Italy)



Technology Centre (Czech Republic)



IoN (UK)



W&W (Spain & The Netherlands)



VTT (Finland)



Yole Développement (France)



MATIMOP- (Israel)



VDI/VDE-IT (Germany)

E. Mantovani



# The Project Timeline

**JANUARY 2004**

**START OF THE PROJECT**

**ASSESSMENT OF THE SITUATION**  
*PREPARATION OF 3 SECTORAL REPORTS*

**NOVEMBER 2004**

**ROME NRM INTERNATIONAL CONFERENCE**  
*PRESENTATION OF 3 SECTORAL REPORTS*  
*SELECTION OF THE 12 TOPICS TO BE ROADMAPMED*

**DEC 2004 – NOV 2005**  
**ROADMAP ELABORATION**

**NOVEMBER 2005**  
**NRM CONFERENCES**  
*ROADMAPS PRESENTATION*

**DECEMBER 2005**  
**END OF THE PROJECT**

*E. Mantovani*

## Countries surveyed

Australia	France	Korea	Slovakia
Austria	Germany	Latvia	Slovenia
Belgium	Greece	Lithuania	Spain
Canada	Hungary	Netherlands	Sweden
China	India	Norway	Switzerland
Czech Republic	Ireland	Poland	Taiwan
Denmark	Israel	Portugal	UK
Estonia	Italy	Russia	USA
Finland	Japan	Singapore	

PUBLIC EXPENDITURES TO SUPPORT R&D IN NANOTECHNOLOGY WITHIN THE 35 COUNTRIES SUEVEYED RESULTED TO BE **IN 2003 AROUND US\$ 3.1 BLN.**

*E. Mantovani*

# Topics Selection

A NUMBER OF TOPICS REPRESENTATIVES OF NANOTECHNOLOGY APPLICATION WERE IDENTIFIED IN EACH OF THE THREE SECTORS CONSIDERED.

BASING ON A SET OF CRITERIA AGREED UPON BY THE CONSORTIUM, DISCUSSION WITH INTERNATIONAL EXPERTS OF NANOTECHNOLOGY, INPUT FROM THE INTERNATIONAL CONFERENCE, WERE SELECTED **FOUR TOPICS FOR EACH SECTOR**.

THE TOPICS WERE VALIDATED IN DIALOGUE WITH THE EUROPEAN COMMISSION


# Roadmaps Elaboration

FOR THE PREPARATION OF THE ROADMAPS A DELPHI – LIKE APPROACH WAS USED BASED UPON A TWO CYCLES EXERCISE CONSISTING IN:

- 1) SELECTING TOP INTERNATIONAL EXPERTS ON THE FIELD
- 2) PREPARATION OF A DEDICATED QUESTIONNAIRE FOR EACH OF THE TOPIC TO BE ROAD MAPPED
- 3) CIRCULATING THE QUESTIONNAIRES AMONG THE EXPERT AND GATHERING OF THEIR RESPONSES **(1ST CYCLE)**
- 4) PREPARATION OF A FIRST SUMMARY/DRAFT ROADMAP FROM THE GIVEN ANSWERS
- 5) CIRCULATING THE DOCUMENT AMONG THE EXPERTS, ASKING FOR COMMENTS AND FEEDBACKS **(2ND CYCLE)**
- 6) ELABORATION OF THE FINAL ROADMAPS

# Experts by Country


The Total number of experts contacted was about 350, around 60% (213) completed the Delphi Exercise.



Others (below 3%) : Austria, Australia, Finland, Ireland, Slovenia, Slovak, Republic, Poland, Japan, Portugal, South Africa, Taiwan, Russia, Estonia, Turkey

E. Mantovani

# Experts by Organization Type



# MATERIALS ROADMAPS


*E. Mantovani*

---




# Topics Selection

- 1) Nanostructured materials
- 2) Nanoparticles / nanocomposites
- 3) Nanocapsules
- 4) Nanoporous materials
- 5) Nanofibres
- 6) Fullerenes
- 7) Nanowires
- 8) Single-Walled & Multi-Walled  
(Carbon) Nanotubes
- 9) Dendrimers
- 10) Molecular Electrics
- 11) Quantum Dots
- 12) Thin Films



- 1) Nanoporous materials
- 2) Nanoparticles/nanocomposites
- 3) Dendrimers
- 4) Thin Films & coatings

# Dendrimers




A DENDRIMER IS GENERALLY DESCRIBED AS A MACROMOLECULE, WHICH IS CHARACTERIZED BY ITS HIGHLY BRANCHED 3D STRUCTURE THAT PROVIDES **A HIGH DEGREE OF SURFACE FUNCTIONALITY AND VERSATILITY**. ITS STRUCTURE IS ALWAYS BUILT AROUND A CENTRAL MULTI-FUNCTIONAL *CORE MOLECULE*, WITH *BRANCHES* AND *END-GROUPS*.

DENDRIMERS CAN BE MADE OUT OF VIRTUALLY ANYTHING THAT CAN BRANCH (METAL ATOMS, ORGANOMETALLIC GROUPS, OR PURELY ORGANIC MATERIALS) AND THEY CAN HAVE A VARIETY OF FUNCTIONALITIES DEPENDING WHAT THEY ARE BUILT OF AND HOW.

# Impact/Advantages

- Polyvalency
- Defined architecture, size and shape control
- Monodispersity
- Loading capacity (“molecular container”)
- Biocompatibility/Low toxicity
- Transfection Properties



# Some of Possible Applications


- **DYES , PAINTINGS, INDUSTRIAL ADHESIVES**
- **INKS/LASER-PRINTING TONERS**
- **POLYMER&PLASTIC ADDITIVES**
- **CATALITIC AGENTS**
- **TARGETED DELIVERY SYSTEMS**
- **MRI CONTRAST AGENTS**
- **CELLULAR TRANSPORT**
- **DIAGNOSTIC&ANALYSIS**
- **LIGHT ARVESTING SYSTEMS**
- **OLED**
- **BUILDING BLOCKS FOR NANOSTRUCTURED MATERIALS**
- **DECONTAMINATION AGENTS**

# Time to market: Situation at 2005


Dendrimer research is very much application-oriented.

Development timeframes of different applications are difficult to estimate.


Barriers are not so much linked to the synthesis or the functionalisation, but to the final application being researched and the cost for a given volume.




# Time to market: Situation at 2010



# Time to market: Situation at 2015



# Estimated market growth vs. risk involved



# Some Barriers to Breakthrough

- **HIGH COSTS FOR SYNTHESIS AND FUNCTIONALIZATION:**
  - *A LIMITING FACTOR FOR MATERIALS APPLICATIONS*
  - *LESS IMPORTANT IN MEDICAL APPLICATIONS*
- **PROCESS CONTROL METHODS, SPECIFICATION and FINAL PRODUCT ANALYTICAL METHODS ARE NEEDED TO ENSURE REPRODUCIBLE, HIGH PURITY AND WELL DEFINED PRODUCTS.**
- **POSSIBLE HSE IMPACT**

# HEALTH AND MEDICAL SYSTEMS ROADMAPS


## Topics Selection

- 1) Tissue Engineering/  
Regenerative Medicine
- 2) Bio Nano Structures
- 3) Drug Encapsulation /  
Drug Delivery /  
Drug Targeting
- 4) Molecular Imaging
- 5) Biophotonics
- 6) Biocompatible implants
- 7) Biomimetic Membranes
- 8) Biomolecular sensors
- 9) Biochips/  
High Throughput Screening
- 10) Lab-on-a-chip
- 11) Functional Molecules:  
Switches, pumps,  
means of transportation



- 1) Drug encapsulation/  
Drug delivery/  
Drug targeting
- 2) Molecular Imaging/  
Biophotonics  
Biochips/
- 3) High-Throughput Screening/  
Lab-on-a-chip technology
- 4) Biomolecular Sensors

# Drug Encapsulation/ Drug Delivery/Drug Targeting



Source: Capsulation NanoScience AG


**NANOTECHNOLOGY WILL BE INCREASINGLY USED TO ANSWER THE DEMAND FOR EVER MORE SPECIFIC DRUGS AND DIAGNOSTIC AGENTS BY MAKING POSSIBLE THE CREATION OF SYSTEMS WHICH CAN ALLOW THE DRUGS TO BE DELIVERED TO DISTINCT AREAS WITHIN THE BODY TO PROVIDE A BETTER AND MORE EFFECTIVE WAY OF TREATMENT.**

# Main Advantages of Nanoparticles for Drug Encapsulation/...

- SPECIFICALLY DRIVEN GUIDANCE COMBINED WITH A SUITABLE ENCAPSULATION IN A NANOPARTICULATE FORM.
- ABILITY TO OVERCOME BIOLOGICAL BARRIERS (SUCH AS PERMEATE THROUGH CELL WALLS).
- ABILITY TO RELEASE DRUGS IN A CONTROLLED MANNER.
- FUNCTIONALIZATION FOR TARGETING AND TO BE DETECTED BY DIAGNOSTIC SYSTEMS.
- LARGE SURFACE/VOLUME RATIO RESULTING IN ENHANCED ACTIVITY.

# Expected Impact/Advantages

- Reduced drug degradation
- Specificity
- Less side-effects
- Longer therapy duration
- Administration of difficult deliverable pharmaceuticals
- “Solubilisation”
- Controlled drug release




# The Nano-particles


SEVERAL TYPES OF NANOPARTICLES ARE USED:

- **INORGANIC NANOPARTICLES** (EX. GOLD, SILICATE, CALCIUM PHOSPHATE, MAGNETIC NANOPARTICLES, ETC.);
- **POLYMER NANOPARTICLES** (EX. POLYSACCHARIDES, POLY LACTIC ACID, POLYACRILATES, ETC.);
- **POLYMER THERAPEUTICS** (EX. POLYMER DRUGS, POL. DRUG CONJUGATES, POL. MICELLES, ETC.);
- **NANOCRYSTALS** (EX. NANO-SIZED MILLED DRUGS);
- **LYPOSOMES.**


# Most Suitable Nanoparticles



# Time to Market



# Gaps and Barriers in Nano-Drug Delivery/.....




**Lack of nanoparticles:  
Investigation on new  
type of nanoparticles  
is needed!**

**Side effects (general  
cell toxic effects!!)**

**Insufficient targeting  
(coupling of specific  
particle-linked side-  
groups to their  
correspondent target  
molecule)**

Expected bottlenecks in R&D



## NANO-RELATED DRUG THERAPY IS STILL AT ITS EARLY STAGE

- **DRUG RELEASE AND THERAPY RESULTS AS THE MOST PROMISING AND IMPORTANT FIELD OF APPLICATION WITH TARGET ORIENTED THERAPY TAKING THE LEAD BY 2015.**
- **INORGANIC NANOPARTICLES AND POLYMER NANOPARTICLES ARE CONSIDERED THE MOST APPROPRIATE NANOPARTICLES (NP), EVEN THOUGH EXPERTS AGREE THAT CURRENTLY AVAILABLE NP IS INSUFFICIENT TO SOLVE ALL EXISTING DRUG - DISTRIBUTION PROBLEMS.**
- **THE NARROW SPECTRUM OF SUITABLE NP AND INADEQUATE TARGETING ARE THE MAIN BOTTLENECKS IN R&D.**
- **SCALABILITY OF NP PRODUCTION, MANUFACTURING STANDARDS FOR NANOMATERIALS AND A DEEPENED KNOWLEDGE OF NP PROPERTIES ARE CHALLENGES TO FACE IN THE FUTURE**
- **SAFETY ISSUES OF NP (ex. CELL TOXICITY) MUST BE CONSIDERED WITH RESPECT, BESIDES CLINICAL USE, TO THE ENVIRONMENTAL AND MANUFACTURING.**

# ENERGY ROADMAPS

# Topics Selection

- 1) Solar cells
- 2) Fuel cells
- 3) Thermoelectricity
- 4) Rechargeable batteries
- 5) Supercapacitors
- 6) Hydrogen storage
- 7) Insulation
- 8) Glazing Technology for Insulation
- 9) More efficient lighting
- 10) Combustion

- 1) Solar cells
- 2) Thermoelectricity
- 3) Rechargeable Batteries and Supercapacitors
- 4) Heat Insulation and Conduction

*E. Mantovani*

Source:



# Solar Cells

**SILICON IS CURRENTLY THE MOST COMMON ELEMENT USED TO MANUFACTURE SOLAR CELLS, TO CONVERT DIRECTLY SUN ENERGY INTO ELECTRIC ENERGY BUT OTHER INORGANIC AND ORGANIC MATERIALS AT NANOSCALE BEING DEVELOPED LOOK PROMISING:**

## **CRYSTALLINE SOLAR CELLS**

*(PRESENTLY MONO AND POLYCRISTALLINE SILICON)*

## **AMORPHOUS/THIN FILMS**

*(CURRENTLY AMORPHOUS SILICON, COPPER INDIUM DISELINIDE)*

## **ORGANIC DYE SENSITISED**

*(TITANIUM DIOXIDE NANOPARTICLES&DYES)*

## **POLYMER CELLS**

*(ADDITION OF LIGHT ABSORBING NANOMATERIALS IN CONDUCTIVE POLYMERS, EX. POLYPHENYLENE VINYLENE)*

## **QUANTUM DOTS**

*(NANOSCALE CRYSTALS SEMICONDUCTORS)*

## **QUANTUM WELLS**

*(UNLTRATHIN LAYER SEMICONDUCTORS)*


## **CARBON NANOTUBES and FULLERENE**

# Impact/Advantages from Nanotechnology

**Advantages:**  
Increase efficiency  
Decrease costs


**Major focus:**  
-Thin films,  
-Nanocrystalline materials  
-Nanoparticles

**Most revolutionary properties in nanomaterials compared with existing technologies**



Nanotechnology will play a relatively minor role in market applications in 2010, strengthening by 2015.

## According to the experts, current nanotechnological progress is advanced ....




- dye-sensitized solar cells
- nanostructured solar cells
- carbon nanotubes
- molecular modeling
- advances and applications in chemical synthesis
- ionic liquids (and their semi-solidification)




- solid organic electrolytes
- charge separation/efficiency
- high gas barrier films
- air-stable polymers
- efficient thin-film modules
- commercially available nanotechnology-based solar cells


# Time to market: Situation at 2005



# Time to market: Situation at 2010



# Time to market: Situation at 2015




- **AT PRESENT NANOTECHNOLOGY IMPACT ON SOLAR CELLS IS IN THE BASIC RESEARCH PHASE.**
- **NANO-THIN FILMS ARE SEEN AS THE MOST PROMISING AREA IN THE MEDIUM TERM.**
- **FIRST APPLICATIONS ARE EXPECTED FOR 2010, TO BE WELL ESTABLISHED BY 2015 .**
- **CELLS INCORPORATING NANOCRISTALLYNE MATERIALS AND DYE-BASED WILL CLOSELY FOLLOW THIN FILMS TO REACH COMMERCIALISATION BY 2015.**
- **TECHNOLOGIES INCLUDING QUANTUM DOTS, FULLERENES AND CARBON NANOTUBES ARE NOT EXPECTED TO SEE FULL COMMERCIAL APPLICATION BEFORE 2015.**

# General Challenges Over the Next Decade

- **REDUCE COSTS OF BOTH THE FABRICATION PROCESS AND FINAL PRODUCTS.**
- **INCREASE RELIABILITY.**
- **INCREASE EFFICIENCY OF FABRICATION AND PRODUCT.**
- **INCREASE LIFETIME.**
- **DEVELOP INNOVATIVE LIGHT TRAPPING STRUCTURES.**
- **OBTAIN AND STABILISE NANOPARTICLE CONCENTRATION AT >60%.**
- **NEW TECHNIQUES TO FORM ACTIVE LAYERS IN THIN FILM SOLAR CELLS.**
- **IMPLEMENT NANOTECHNOLOGY INTO INORGANIC SOLAR CELLS.**

# Research and technology development underway

Basic research underway with the technology developments required to achieve the desired applications



# Conclusion...

**NANOTECHNOLOGY IS POSED TO REVOLUTIONISE THE INDUSTRIAL LANDSCAPE AND EVERY DAY LIFE.**

**FOR THIS TO HAPPEN TO THE FULL THE WAY IS, HOWEVER, STILL LONG.**

**THE ROADMAPS PROVIDE A COHERENT SCENARIO ABOUT THE POSSIBLE EVOLUTION OF NANOTECHNOLOGY APPLICATION IN THE THREE SECTORS CONSIDERED, USEFUL TO OPTIMISE AND BETTER ADDRESS THE EFFORTS IN THESE FIELDS.**

**RESEARCHERS, PUBLIC BODIES, THE EC INFIRST PALCE FOR FP7, INDUSTRIES (IN PARTICULAR SMEs), POLICY MAKERS, PLANNERS, THE FINANCIAL COMMUNITY, CAN ALL TAKE ADVANTAGE OF THEM.**

**THANKS FOR YOUR  
ATTENTION!**


**Elvio Mantovani, Andrea Porcari**

**[www.nanotec.it](http://www.nanotec.it) - [info@nanotec.it](mailto:info@nanotec.it)**

**AIRI/Nanotec IT  
Viale Gorizia 25/C, Rome (ITALY)**

*E. Mantovani*

---



**nanotec IT**  
CENTRO ITALIANO PER LE NANOTECNOLOGIE

**Airi**  
Associazione  
Italiana  
per la ricerca  
industriale